Review
Cell Biology
Mohammad Reza Zinatizadeh, Peyman Kheirandish Zarandi, Mohsen Ghiasi, Hamid Kooshki, Mozafar Mohammadi, Jafar Amani, Nima Rezaei
Summary: New findings suggest that targeting aging pathways can improve the treatment of COVID-19. Boosting the immune system with new therapies can help elderly individuals with comorbidities fight against severe forms of the virus.
AGEING RESEARCH REVIEWS
(2023)
Review
Pharmacology & Pharmacy
Chunjue Yuan, Ruoyun Li, Guohong Liu, Yunbao Pan
Summary: Since the outbreak of the new coronavirus at the beginning of 2020, despite a stable situation in China, the global spread of COVID-19 continues without specific therapeutic drugs or vaccines available. The main cause of death for severe patients is an uncontrolled cytokine storm, highlighting the importance of immune-related research for the prevention and treatment of COVID-19.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Edouard Charles Le Carpentier, Emmanuel Canet, Damien Masson, Maelle Martin, Guillaume Deslandes, Aurelie Gaultier, Eric Dailly, Ronan Bellouard, Matthieu Gregoire
Summary: In this study, the impact of inflammation on the pharmacokinetics of midazolam in COVID-19 patients was investigated. The results suggest that inflammation could reduce the metabolism of midazolam by CYP3A. Therefore, caution should be exercised when administering drugs metabolized by CYP3A in cases of severe inflammation.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Health Care Sciences & Services
Mai Abdel Haleem Abusalah, Moad Khalifa, Mohammad A. Al-Hatamleh, Mu'taman Jarrar, Rohimah Mohamud, Yean Yean Chan
Summary: COVID-19 continues to be a global threat, and finding effective antiviral agents is crucial. Nucleic acid-based therapeutics, particularly miRNAs, have shown potential in controlling the disease, especially by suppressing the cytokine storm phenomenon.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Virology
Oleksandr Oliynyk, Wojciech Barg, Anna Slifirczyk, Yanina Oliynyk, Vitaliy Gurianov, Marta Rorat
Summary: The study identified three subtypes of cytokine storm in COVID-19 patients: CRS, MAS, and sepsis. Tocilizumab therapy was associated with reduced mortality in MAS patients but increased mortality in CRS patients.
Review
Medicine, Research & Experimental
Jae Seok Kim, Jun Young Lee, Jae Won Yang, Keum Hwa Lee, Maria Effenberger, Wladimir Szpirt, Andreas Kronbichler, Jae Il Shin
Summary: Severe COVID-19 is characterized by systemic hyper-inflammation and cytokine storm, often leading to acute respiratory distress syndrome and multiple organ failure. Treatment of COVID-19 cytokine storm is crucial, with anti-inflammatory therapies playing a significant role. Various approaches are being used, including new cytokine-targeted therapies, to address the cytokine storm associated with COVID-19.
Article
Multidisciplinary Sciences
David Garcia-Azorin, Alvaro Sierra, Javier Trigo, Ana Alberdi, Maria Blanco, Ismael Calcerrada, Ana Cornejo, Miguel Cubero, Ana Gil, Cristina Garcia-Iglesias, Ana Guiomar Lozano, Cristina Martinez Badillo, Carol Montilla, Marta Mora, Gabriela Nunez, Marina Paniagua, Carolina Perez, Maria Rojas, Marta Ruiz, Leticia Sierra, Maria Luisa Hurtado, Angel Luis Guerrero Peral
Summary: Headache occurred in 23.4% of patients with confirmed COVID-19, being more intense in females. Headache was the most frequent first symptom of COVID-19, with characteristics of being bilateral with pressing quality and typically lasting for 7 days.
SCIENTIFIC REPORTS
(2021)
Editorial Material
Medicine, Research & Experimental
Hugh Rosen, Michael B. A. Oldstone
Summary: In this study, the researchers explored the association between S1P serum levels and the severity of COVID-19, proposing a new prognostic indicator.
EMBO MOLECULAR MEDICINE
(2021)
Article
Neurosciences
Dipak Kumar, Sadaf Jahan, Andleeb Khan, Arif Jamal Siddiqui, Neeru Singh Redhu, Wahajuddin, Johra Khan, Saeed Banwas, Bader Alshehri, Mohammed Alaidarous
Summary: The ongoing COVID-19 pandemic has been associated with extrapulmonary infections and manifestations, with a potential neurotropic effect of coronaviruses posing a risk to neuronal tissue. Neuronal symptoms like ageusia, anosmia, and neurological disorders have been reported in COVID-19 patients, highlighting the neurological impact of the disease. The interdependence between the brain, pulmonary organs, and systemic circulation may exacerbate the pathophysiological aspects of COVID-19, emphasizing the need for a holistic approach to treating patients with neurodegenerative or neuropsychological conditions. Vaccines are being developed as a top priority to combat the spread of the virus and address the neurological complications.
MOLECULAR NEUROBIOLOGY
(2021)
Review
Pharmacology & Pharmacy
Yaqun Li, Wenjie Zhao, Jinhua Liu, Zichao Chen, Qingtao Lv, Zhen Zhang
Summary: COVID-19 pneumonia, caused by SARS-CoV-2, has disrupted the pro-inflammatory/anti-inflammatory response, leading to a need to neutralize cytokine storm. Current treatments focus on vaccines for prevention and immunomodulatory therapies to alleviate immune imbalance, with antiviral drugs and respiratory support as clinical options.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Immunology
Ayesha Tanveer, Bushra Akhtar, Ali Sharif, Uzma Saleem, Azhar Rasul, Aftab Ahmad, Kashif Jilani
Summary: Covid-19, originating from China, is a rapidly spreading pandemic caused by the immune system's disproportionate response to the coronavirus. This systemic inflammatory reaction, known as cytokine release storm, leads to pulmonary inflammation, hypercoagulation, and thrombosis. Individuals with pre-existing inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, diabetes mellitus, and tuberculosis are more susceptible to morbidity and complications from COVID-19. This review focuses on the pathogenesis of COVID-19 and cytokine release storm in patients with comorbidities, as well as briefly discussing available therapeutic regimens and emerging medications in clinical trials.
INFLAMMOPHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Xiaokang He, Fei Yao, Jie Chen, Yan Wang, Xiangming Fang, Xuan Lin, Hui Long, Qiang Wang, Qingming Wu
Summary: The study found that D-dimer levels are closely related to the clinical classification and prognosis of COVID-19 patients, with a D-dimer value of 2.025 mg/L regarded as the optimal probability cutoff for predicting death. Advanced age, male gender, dyspnea symptoms, and some underlying diseases are influencing factors for D-dimer levels.
SCIENTIFIC REPORTS
(2021)
Article
Immunology
Ali Ameri, Masoomeh Frouz Asadi, Ava Ziaei, Majid Vatankhah, Omid Safa, Manoochehr Kamali, Mohammad Fathalipour, Masoumeh Mahmoodi, Soheil Hassanipour
Summary: The study evaluated the efficacy and safety of oral melatonin in patients with COVID-19-induced pneumonia. The results showed that melatonin significantly reduced mortality rate and requirement of IMV, as well as shortened hospitalization and time to clinical status improvement.
INFLAMMOPHARMACOLOGY
(2023)
Article
Immunology
Jianbo Tian, Ming Zhang, Meng Jin, Fengqin Zhang, Qian Chu, Xiaoyang Wang, Can Chen, Huihui Yue, Li Zhang, Ronghui Du, Dong Zhao, Zhaofu Zeng, Yang Zhao, Kui Liu, Mengmei Wang, Ke Hu, Xiaoping Miao, Huilan Zhang
Summary: This study found that tocilizumab treatment in COVID-19 patients can lower the risk of in-hospital death and acute respiratory distress syndrome. Patients had heightened inflammation and dysregulated immune cells before treatment, but these indicators improved after tocilizumab administration.
JOURNAL OF IMMUNOLOGY
(2021)
Article
Infectious Diseases
Zheng Liu, Fang Shi, Jun-Xia Liu, Jia-Qi Liu, Jing Li, Qian Wang, Hui Wang, Chang-Lan Gao, Jian-Min Li, Dong-Fang Zhao
Summary: The use of corticosteroids in severe COVID-19 patients has been shown to reduce mortality rates in clinical trials recommended by the WHO and conducted in different countries, but its safety remains controversial. Administering corticosteroids at the appropriate timing and dosage in the early stages of COVID-19 pneumonia deterioration can effectively alleviate the condition.
INFECTION AND DRUG RESISTANCE
(2021)